Use of tetrabenazine in huntington disease patients on antidepressants or with advanced disease: Results from the TETRA-HD study

PLoS Currents

Volumn , Issue , 2011, Pages

  Dorsey, Ray ^a   Biglan, Kevin ^b   Eberly, Shirley ^b   Auinger, Peggy ^b   Brocht, Alicia ^b   Umeh, Chizoba C ^a   Oakes, David ^b   Clarence Smith, Kathleen ^d   Marshall, Frederick ^e   Shoulson, Ira ^c,f   Frank, Samuel ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c University of Rochester Medical Center ^*  (United States)

^d Neurology University of Rochester School of Medicine and Dentistry   (United States)

^e UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^f Program for Regulatory Science and Medicine (PRSM)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; TETRABENAZINE; PLACEBO;

ARTICLE; CHOREA; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUNTINGTON CHOREA; MOOD; RANDOMIZED CONTROLLED TRIAL; DRUG EFFECT; INCIDENCE; MAJOR CLINICAL STUDY; MOOD CHANGE; RATING SCALE;

EID: 84863681449     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: 10.1371/currents.RRN1283     Document Type: Article

References (11)

1. Huntington Study Group (2006) Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66: 366-372.
2. Hayden MR, Leavitt BR, Yasothan U, Kirkpatrick P (2009) Tetrabenazine. Nat Rev Drug Discov 8: 17-18.
3. Pearson SJ, Reynolds GP (1988) Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. Neuropharmacology 27: 717-719.
4. Pettibone DJ, Totaro JA, Pflueger AB (1984) Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur J Pharmacol 102: 425-430.
5. Delgado PL (2000) Depression: the case for a monoamine deficiency. J Clin Psychiatry 61 Suppl 6: 7-11.
6. Jankovic J, Beach J (1997) Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 48: 358-362.
7. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, et al. (1996) Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51: 73-78.
8. Ho A, Hocaoglu M (2011) Impact of Huntington's across the entire disease spectrum: the phases and stages of disease from the patient perspective. Clin Genet 80: 235-239.
9. Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, et al. (2010) Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY. PLoS Curr 2.
10. Frank S (2009) Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol 9: 62.
11. Huntington Study Group (2011) Cooperative Huntington's Observational Research Trial (COHORT). Retrieved August 29, 2011, from http://www.huntington-studygroup.org/ClinicalResearch/ClinicalTrialsObservationalStudiesinProgress/COHORT/tabid/83/Default.aspx.